OriGene Technologies completed a $16 million Series B financing. The proceeds from the funding will be used to continue building its TrueMAB™ monoclonal antibody collection.
“The funding will propel us closer to meeting our goal of building the largest monoclonal antibody collection in the world covering the entire human genome of approximately 20,000 genes,” says Wei-Wu He, OriGene's chairman and CEO.
The TrueMAB collection will consist of antibodies that are significantly different from many on the market, as OriGene will be using authentic human full-length proteins as immunogens during the manufacturing process, the company points out. Over the last decade OriGene has built what it believes to be the largest collection of human full-length cDNA clones in the world.
TrueMAB antibodies have been proven to be superior in quality than traditional small peptide generated monoclonal and polyclonal antibodies, especially in applications such as flow cytomery and multiplex ELISA assays, according to Origene.
OriGene's product line also includes shRNA clone collections, over 5,000 purified human proteins, 100,000 highly validated human tissues, and Luminex multiplex assay products. Additionally, OriGene provides a broad range of antibody-validation products including genome-wide tagged antigen standards and IHC slides derived from its tissue collection.
The Series B financing was led by IDG-Accel, SBI & TH Venture Capital Enterprise, and Zero2IPO. OriGene's previous investors Morningside Venture Investments and President International Development also participated.